anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Physical therapists have an important role as initial contact providers for individuals with musculoskeletal disorders. Health care expenditures are on the rise each year in the U.S. and a large proportion is due to musculoskeletal disorders. Despite the rise in spending, there has not been an improvement in outcomes for individuals with musculoskeletal disorders. Furthermore, increased medical spending and utilization could expose patients to iatrogenic harm. Comparative effectiveness studies of different portals of entry would help to determine the most effective pathways for individuals with musculoskeletal disorders to seek care. The purpose of this study is to determine whether patients with musculoskeletal injuries do better by seeing a primary care provider first versus seeing a physical therapist first. Subjects will be enrolled from two sites (Temple University, Philadelphia, PA and Brooke Army Medical Center, San Antonio, TX). Patient self-reported outcomes measures will be collected at baseline and 6 weeks. At 6 months, healthcare utilization will be assessed. The investigators plan to enroll a target sample size of 75 subjects per site (150 total). Descriptive statistics will be computed to characterize the 2 treatment groups with ANCOVA being used to assess differences between treatment groups at 6 weeks, adjusting for baseline values, evaluating the assumption of parallel slopes. The investigators will further investigate sources of systematic differences in response to treatment using methods such as generalized estimating equations and linear mixed effects models. This research will be the first multi-site study to compare effectiveness of these two pathways for individuals with musculoskeletal pain in the U.S. With a growing older adult population, the percentage of individuals who have musculoskeletal pain in the U.S. will only increase over time. This research study is timely and could meet the need for identifying the most effective pathway for individuals with musculoskeletal pain to seek care.
PURPOSE:To obtain water- and oil-repellent powder for cosmetics excellent in water and oil repellency and touch after use, especially smoothness by treating the surface of powder with a multivalent. metallic salt of an acylated amino acid or a multivalent metallic salt of amidosulfonic acid and a compd. having a perfluoroalkyl group contg. a specified number or more of C atoms. CONSTITUTION:The surface of powder is treated with a multivalent metallic salt of an acylated amino acid represented by formula I and/or a multivalent metallic salt of amidosulfonic acid represented by formula II and a compd. having a straight or branched chain >=6C perfluoroalkyl group in the molecule to obtain the objective water- and oil-repellent powder. In the formula I, R is straight or branched chain 7-21C alkyl, etc., M<1> is a multivalent metal atom, x is a number of 1-11, m is the valence of M<1> and n is a number of 1-4. In the formula II, R<2> is straight or branched chain 7-21C alkyl, etc., R<3> is H, etc., M<2> is a multivalent metal atom, Y is ethylene, etc., p is the valence of M<2> and q is 1-4.
Participants with p16/HPV-negative recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) will be assigned to Cohort A. Participants will be administered lead-in low dose gemcitabine (LDG) 10 mg/m2 IV Day -7 (+/- 3 days, before Cycle 1 only) followed by ACR-368 105 mg/m2 IV every 2 weeks and LDG 10 mg/m2 every 2 weeks until discontinuation due to disease progression, intolerability, or consent withdrawal. When delay or discontinuation of the treatment is necessary, both ACR-368 and LDG will be delayed or discontinued together.
PROBLEM TO BE SOLVED: To provide a sufficiently sterilized medical container capable of stably maintaining the concentration of bicarbonate and preserving it for a long time and also provide a method for manufacturing the medical container. SOLUTION: This medical container 71 is a container for storing an electrolyte solution 72 as an infusion liquid and is formed in a pliable and flexible resin. In addition, the container 71 has plural chambers 74, 75 and an isolating wall 76 is formed in such a manner that it is openable from the outside of container 71 when it is used. Further, bicarbonate 73 in a solid state is stored in isolated fashion, in the chamber 75, and the container 71 is sterilized using an autoclave. The isolating wall 76 between the chambers 71, 75 is openable from the outside of container 1 when it is used, so that the bicarbonic acid solution 73 is mixed, in a sterile state, with the electrolyte solution 72, and an infusion liquid containing bicarbonic acid is prepared in the container 1.  Besides, as the bicarbonate 73 is stored in a solide state, its decomposition is almost entirely inhibited even at the time of autoclave sterilization process at high temperatures.
Patients receive abraxane IV over 30 minutes and romidepsin IV over 60 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
A unitarily molded toothbrush is provided including a head with bristles integrally molded therewith, a handle and a neck, all being formed of an identical plastic material, preferably a polyolefin resin, having a Melt Index no lower than 6 g/10 min. At least one recess is formed with respective opening in an undersurface of the handle of the toothbrush. In alternative embodiments, recesses and their openings can also be found in the neck and head. These embodiments may include a beam flanked by the recess openings longitudinally traversing the length of the handle, and optionally also traversing the neck and head. Cross members may be formed orthogonal to the beam to strengthen the structure. Also provided is a kit for dental hygiene which includes the unitarily molded toothbrush in combination with a dentifrice to improve the delivery of flavor or a therapeutically active substance such as a source of fluoride.
PURPOSE: A Ravenala madagascariensis extract is provided to maintain and strengthen skin moisturizing. CONSTITUTION: A plant extract is isolated from Ravenala madagascariensis sap. A hydro alcoholic extract is obtained from young leaves of Ravenala madagascariensis using mixture of ethanol and water. A formulation for skin moisturizing contains the Ravenala madagascariensis sap or extract isolated from young leaves of Ravenala madagascariensis. A cosmetic composition contains the Ravenala madagascariensis sap and the extract. The composition is manufactured in the form of serum, lotion, cream, hydrogel, mask, stick, or patch.
PURPOSE: Diabetes and its complications cause a heavy burden of disease worldwide. In recent years, Mendelian randomization (MR) has been widely used to discover the pathogenesis and epidemiology of diseases, as well as to discover new therapeutic targets. Therefore, based on systematic "druggable" genomics, we aim to identify new therapeutic targets for diabetes and analyze its pathophysiological mechanisms to promote its new therapeutic strategies.
MATERIAL AND METHOD: We used double sample MR to integrate the identified druggable genomics to evaluate the causal effect of quantitative trait loci (eQTLs) expressed by druggable genes in blood on type 1 and 2 diabetes (T1DM and T2DM). Repeat the study using different data sources on diabetes and its complications to verify the identified genes. Not only that, we also use Bayesian co-localization analysis to evaluate the posterior probabilities of different causal variations, shared causal variations, and co-localization probabilities to examine the possibility of genetic confounding. Finally, using diabetes markers with available genome-wide association studies data, we evaluated the causal relationship between established diabetes markers to explore possible mechanisms.
RESULT: Overall, a total of 4,477 unique druggable genes have been gathered. After filtering using methods such as Bonferroni significance (P<1.90e-05), the MR Steiger directionality test, Bayesian co-localization analysis, and validation with different datasets, Finally, 7 potential druggable genes that may affect the results of T1DM and 7 potential druggable genes that may affect the results of T2DM were identified. Reverse MR suggests that C4B may play a bidirectional role in the pathogenesis of T1DM, and none of the other 13 target genes have a reverse causal relationship. And the 7 target genes in T2DM may each affect the biomarkers of T2DM to mediate the pathogenesis of T2DM.
CONCLUSION: This study provides genetic evidence supporting the potential therapeutic benefits of targeting seven druggable genes, namely MAP3K13, KCNJ11, REG4, KIF11, CCNE2, PEAK1, and NRBP1, for T2DM treatment. Similarly, targeting seven druggable genes, namely ERBB3, C4B, CD69, PTPN22, IL27, ATP2A1, and LT-β, has The potential therapeutic benefits of T1DM treatment. This will provide new ideas for the treatment of diabetes and also help to determine the priority of drug development for diabetes.
Specific Aim 1. Determine the safety, tolerability and maximum tolerated dose (MTD) of pacritinib in combination with bemcentinib in patients with advanced lung adenocarcinoma. We propose a prospective, open-label, phase Ib trial to evaluate safety, tolerability and MTD of pacritinib (JAK2 inhibitor) in combination with bemcentinib (AXL inhibitor) in patients with treatment refractory lung adenocarcinoma. The primary objectives of the phase Ib study are to determine the maximum tolerated dose (MTD), pharmacokinetics/pharmacodynamics (PK/PD), dose-limiting toxicities (DLTs) and efficacy of oral pacritinib in combination with bemcentinib. This phase Ib part of the study will use a Bayesian Optimal Interval (BOIN)70 design to determine MTD. This Bayesian dose-finding approach combines the ease of implementation of the traditional "3+3" design with the improved performance of more complex model-based designs in terms of accurately identifying the MTD. Compared to the modified probability toxicity interval design, it has a substantially lower risk of overdosing patients and generally has a higher probability of correctly selecting the MTD. In the phase Ib part of the study, subjects with advanced lung adenocarcinoma will be treated with pacritinib in combination with bemcentinib at increasing doses until MTD for combination treatment has been established. Six dose levels of combination treatments will be considered.
It has been discovered that a sequential administration by intramuscular electroporation of the gene for IL12 followed about 10 days later by the gene for IL27 eradicated tumors in 33% of mice with aggressive 4T1 breast malignancy. In addition, the mice in which the initial tumor was eradicated rejected subsequent challenges with tumor cells. This simple sequential cytokine gene therapy can be used for treating residual malignancy and for inhibiting metastatic tumors. Tumors that respond to this treatment were shown to have the WSX-1 subunit of the IL27 receptor. The responsiveness of tumors containing WSX-1 to the dual IL12→IL27 therapy suggests that WSX-1 receptor may be used as a marker for selection of sensitive populations of tumor cells. Stat1 phosphorylation was shown to be a useful measure for WSX-1 activation in a panel of various cancer cells.
Counselors will conduct standard treatment during IOP/OP in this condition. Exceptions to this condition are that counselors will: audio record their first 3 biweekly and subsequent 7 monthly individual in-person sessions; document on a Contact Log outreach attempts; and complete a Counselor Activity Log for client participants. There are several steps that counselors typically take when a client misses a session. Clients are called to reschedule for the same week, if the client doesn't return for their next scheduled session, the counselor sends a letter asking the client to return, etc.
Humidified high-flow nasal oxygen delivered via the Optiflow device. Repeated series with 100% oxygen with flows varying between 30 to 50 l/min. Volunteers will also be pre-oxygenated with both opened and closed mouth.
A method of treatment for mesenteric adenitis in humans is provided. The method comprises the administration of antiviral agents comprising pharmaceutical derivatives of imidazole. Specifically, mesenteric adenitis is treated with orally administered dosages of metronidazole or cimetidene. When the treatment is with metronidazole, a preferred dosage for average sized adult humans is approximately 1,000 to 2,000 milligrams administered once a day. When the antiviral agent administered is cimetidine, the preferred dosage is 900 to 1,200 milligrams given two times a day. When either cimetidine or metronidazole are given, concurrent treatment with zinc is suggested as a method of speeding recovery.
The stemness loss-associated dysregeneration of impaired alveolar type 2 epithelial (AT2) cells abolishes the reversible therapy of idiopathic pulmonary fibrosis (IPF). We here report an inhalable mucus-penetrating lipid nanoparticle (LNP) for codelivering dual mRNAs, promoting realveolarization via restoring AT2 stemness for IPF treatment. Inhalable LNPs were first formulated with dipalmitoylphosphatidylcholine and our in-house-made ionizable lipids for high-efficiency pulmonary mucus penetration and codelivery of dual messenger RNAs (mRNAs), encoding cytochrome b5 reductase 3 and bone morphogenetic protein 4, respectively. After being inhaled in a bleomycin model, LNPs reverses the mitochondrial dysfunction through ameliorating nicotinamide adenine dinucleotide biosynthesis, which inhibits the accelerated senescence of AT2 cells. Concurrently, pathological epithelial remodeling and fibroblast activation induced by impaired AT2 cells are terminated, ultimately prompting alveolar regeneration. Our data demonstrated that the mRNA-LNP system exhibited high protein expression in lung epithelial cells, which markedly extricated the alveolar collapse and prolonged the survival of fibrosis mice, providing a clinically viable strategy against IPF.
Increased sequencing depth can improve the detection rate of noninvasive prenatal testing (NIPT) for chromosome aneuploidies and copy number variations (CNVs). However, due to the technical limitations of NIPT, false-positives and false-negatives are inevitable. False-positives for aneuploidy and CNVs have been widely reported, but few missed cases have been reported. In this study, we report 3 patients missed by NIPT, which were still missed after increasing the sequencing depth. To verify the detection efficiency of the platform, the results of NIPT in 32,796 patients treated in Yulin Women and Children Health Care Hospital from 2020 to 2022 were retrospectively analyzed. Data on false-negative cases found by postnatal follow-up or amniocentesis were collected, and the sequencing data, pregnancy examination data, and postnatal follow-up results of these missed patients were summarized. Five patients missed by NIPT were found, and they were missed again by retesting or increasing the sequencing depth. Except for hypospadias found in 1 patient, ultrasonography of the other 4 patients showed no obvious abnormalities during the whole pregnancy. Our results suggest that pregnant women should be fully informed of the benefits and limitations of NIPT before undergoing the examination to avoid unnecessary medical disputes.
The main objective of this study is to demonstrate the effectiveness of lymphatic drainage and connective tissue techniques in modulating systemic inflammation. Another objective is to evaluate the existence, at baseline, of a correlation between the inflammation indices and the level of adherence to the Mediterranean diet.

Methods. 34 patients were recruited, and divided into three groups. The control group followed the normal rehabilitation protocol. The other two groups were subjected, in addition to the standard treatment, to manual lymphatic drainage treatment or connective tissue techniques. The outcomes (PCR, ESR, Oedema) were recorded in three stages: upon entering the hospital, 1 week after entry and at follow-up 21 days after surgery.
The purpose of the current investigation is to evaluate the generality of FCT as treatment for severe destructive behavior. Again, the effectiveness of FCT in treating destructive behavior has been demonstrated repeatedly both in the investigators' clinic and in other clinics. The investigators are specifically interested in examining the percentage of this population that might benefit from FCT, as well as identifying the subject characteristics of children for whom FCT is and is not effective.

Children with an intellectual disability often display severe destructive behaviors (e.g., aggression, self-injury) that pose significant risks to self or others and represent overwhelming barriers to community integration. These destructive behaviors are often treated with behavioral interventions derived from a functional analysis, which is used to identify the environmental antecedents and consequences that occasion and reinforce the destructive behavior. One such treatment is called functional communication training (FCT), which involves extinction of destructive behavior and reinforcement of an alternative communication response with the consequence that previously reinforced destructive behavior. Results from epidemiological studies and meta-analyses indicate that treatments based on functional analysis, like FCT, typically reduce destructive behavior by 90% or more and are much more effective than other treatments. Despite these impressive findings, there have been no randomized, controlled trials evaluating the effectiveness of FCT. The goal of this study is to determine the robustness of FCT in reducing severe destructive behavior as compared to a waitlist control group.
The process described in the parent Specification in which a hormone preparation is treated with a compound capable of condensing with the hormone and containing in addition to the group which condenses, a group capable of salt formation, and using this salt forming group to effect a separation between the hormone containing compound and bodies which have not condensed, is modified in that in the above process a further subdivision of the esterified and non-esterified fractions is achieved by treatment of the hormone condensation product with aqueous alkaline solutions of various alkalinity in the presence of water immiscible organic solvents.  By this method there is obtained in addition to the separation of the male sex hormone from the follicle hormone, a separation of the various follicle hormones themselves.  The condensing agents which are described in Specification 450,325 may be used to form condensation products which can then be treated according to the present invention.  As starting materials there may be used extracts or preparations such as those obtained from the urine of pregnant individuals, placenta, ovaries and other organs, from vegetable material such as palm oil and the like, extracts from coal, mineral oils and similar products, and synthetic mixtures that are obtained for instance by oxidation of sterols.  In an example a hormone preparation obtained from the urine of mares is fused with phthalic anhydride, dissolved in ether and extracted with dilute sodium carbonate solution.  The ethereal extract is evaporated, saponified with 5 per cent methanolic potassium hydroxide, diluted with water and extracted with ether. The ethereal extract so obtained is extracted several times with 10--15 per cent aqueous potassium hydroxide, and this extract acidified to yield, follicle hormone.  The original sodium carbonate extract is made more strongly alkaline by the addition of potassium hydroxide, whereupon it is saponified, diluted with water and extracted with ether.  The ethereal extract is extracted several times with 10--15 per cent aqueous potassium hydroxide and the extract so obtained acidified to yield d -follicle hormone.  Samples have been furnished under Sect. 2 (5) of (1) d -follicle hormone and (2) follicle hormone obtained from the urine of pregnant mares and separated by an extraction process similar to that described in the above example and set out in tabular form, (3) follicle hormone hydrate, (4) follicle hormone, (5) male sex hormone, (6) pregnandiols obtained from the urine of pregnant women and separated by an extraction process similar to that described in the above example and set out in tabular form.  The Specification as open to inspection under Sect. 91 comprises also the subject-matter of Specification 450,325.  This subject-matter does not appear in the Specification as accepted.
A method for the anti-senescence of and/or rejuvenating a stem cell is provided. The method comprising treating the stem cell with trans-cinnamaldehyde (TC). A kit is also provided. The kit comprising (1) a first part, comprising a stem cell; (2) a second part, comprising TC; and (3) a culture medium of the stem cell, placed in at least one of the first part, the second part, and a third part. In addition, a method for stem cell therapy is provided. The method comprising administering to a subject in need an effective amount of a stem cell, wherein the stem cell has been treated with TC before being administered.
Subjects sign an informed consent form and undergo a medical screening prior to participation. The screening includes a physical exam, anthropometry, chemical and lipid profiles, as well as measures of liver and renal function. The subjects are assigned to one of two groups based upon age.

Subjects participate in five experimental trials, one for each of the five beverages. The beverages are commercially-available and contain ingredients that are generally recognized as safe (GRAS). The order of the beverages is randomized. The list of ingredients on the bottle containing the beverage is obscured. The trials are identical and separated by at least five days. For each experiment, baseline measurements are conducted. Then the subjects consume one liter of the test beverage over thirty minutes. Additional measurements are performed thirty minutes post ingestion and then every hour for four hours post ingestion.

This study yields two BHI numbers for each beverage, one number for each study-group. The BHI numbers are indicative of the amount of fluid remaining in the body four hours after consumption of the beverage. The BHI number is inversely related to the amount of urine produced over the four hours. A greater BHI number indicates better fluid retention and maintenance of plasma volume.